Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
FIT Biotech Oy: FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 15 Sep 2017 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FIT Biotech Oy
FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2017
This company release is a summary of FIT Biotech's Half Year Financial Report January-June 2017, which is available in full in the pdf file attached to this company release. Major research milestone reached in applying GENE delivery vector gtGTU Company highlights January-June 2017
Post period end highlights
Outlook for 2017
Formulas for key financial figures
Equity ratio, %
=
(Total equity + capital loans) x 100
Return on investment (ROI), %
=
(Profit (loss) + financial expences) x 100
Earnings per share
=
Profit (loss) for the period
CEO James Kuo comments FIT Biotech Oy has met a major research milestone in utilizing its novel gene therapy vector gtGTU for producing a therapeutic anticancer antibody in the body. A related patent application has been filed. gtGTU shows promise for gene therapy applications and will open new opportunities for us in several major disease areas, including infectious disease, cancer, regenerative medicine and rare diseases. We continue working closely with our international partners for bringing new groundbreaking therapies to those most in need. Furthest advanced in the pipeline, we have our HIV-vaccine candidate that will be tested in a phase II clinical trial. Our vaccine has the potential of offering patients a safe, long-term therapy for keeping the virus at undetectable levels without antiviral medicines, thus offering a functional cure. Together with our partners at the European HIV Alliance and with the support of the HIV community, we look forward to getting started with the trial in late 2017. We are also exploring possibilities to apply for secondary listing for FIT Biotech shares in the First North Sweden market. We aim to increase awareness of FIT Biotech in the Swedish market and to facilitate trading liquidity.
Publishing of the financial reporting in 2017
General statement
FIT BIOTECH OY Board of Directors
Further information:
Certified Advisor: Aalto Capital Partners Oy, mobile +358 40 5877000
FIT Biotech in brief
FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines. FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.
DISTRIBUTION:
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: FIT Biotech Oy via GlobeNewswire
HUG#2134219
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |